Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 2, pp 315–324

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

  • Fumihiko Kanai
  • Haruhiko Yoshida
  • Ryosuke Tateishi
  • Shinpei Sato
  • Takao Kawabe
  • Shuntaro Obi
  • Yuji Kondo
  • Makoto Taniguchi
  • Kazumi Tagawa
  • Masafumi Ikeda
  • Chigusa Morizane
  • Takuji Okusaka
  • Hitoshi Arioka
  • Shuichiro Shiina
  • Masao Omata
Original Article

DOI: 10.1007/s00280-010-1320-2

Cite this article as:
Kanai, F., Yoshida, H., Tateishi, R. et al. Cancer Chemother Pharmacol (2011) 67: 315. doi:10.1007/s00280-010-1320-2

Abstract

Purpose

We studied the safety and effectiveness of TSU-68, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor and fibroblast growth factor receptor, in patients with advanced hepatocellular carcinoma (HCC).

Methods

Patients with unresectable or metastatic HCC were eligible for enrollment. In phase I, the safety, tolerability and pharmacokinetics were assessed in patients stratified based on liver function, from no cirrhosis to Child–Pugh class B. The safety and effectiveness were assessed in phase II at the dose determined in phase I.

Results

Twelve patients were enrolled in phase I. Dose-limiting toxicities were found with TSU-68 at the dose of 400 mg bid in Child–Pugh B patients, and 200 mg bid was established as the phase II dose. Phase II included 23 additional patients, and the safety and efficacy were evaluated in a total of 35 patients. One patient (2.9%) had a complete response. Two patients (5.7%) had a partial response, and 15 patients (42.8%) showed a stable disease. The median time to progression was 2.1 months, and the median overall survival was 13.1 months. Common adverse events were hypoalbuminemia, diarrhea, anorexia, abdominal pain, malaise, edema and AST/ALT elevation. The analysis of angiogenesis-related parameters suggests that serum-soluble vascular cell adhesion molecule-1 is a possible marker to show the response.

Conclusions

TSU-68 at a dose of 200 mg bid determined by stratification into liver function, showed promising preliminary efficacy with a high safety profile in patients with HCC who had been heavily pre-treated.

Keywords

Advanced HCC Liver function TSU-68 Pharmacokinetics Tolerability Angiogenesis 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Fumihiko Kanai
    • 1
    • 2
    • 7
  • Haruhiko Yoshida
    • 1
  • Ryosuke Tateishi
    • 1
  • Shinpei Sato
    • 1
  • Takao Kawabe
    • 1
  • Shuntaro Obi
    • 3
  • Yuji Kondo
    • 4
  • Makoto Taniguchi
    • 4
  • Kazumi Tagawa
    • 4
  • Masafumi Ikeda
    • 5
  • Chigusa Morizane
    • 5
  • Takuji Okusaka
    • 5
  • Hitoshi Arioka
    • 6
  • Shuichiro Shiina
    • 1
  • Masao Omata
    • 1
  1. 1.Department of GastroenterologyUniversity of TokyoTokyoJapan
  2. 2.Department of Clinical Drug Evaluation, Graduate School of MedicineUniversity of TokyoTokyoJapan
  3. 3.Department of HepatologyKyoundo HospitalTokyoJapan
  4. 4.Department of GastroenterologyMitsui Memorial HospitalTokyoJapan
  5. 5.Hepatobiliary and Pancreatic Oncology DivisionNational Cancer Center HospitalTokyoJapan
  6. 6.Division of Medical OncologyYokohama Rosai HospitalYokohamaJapan
  7. 7.Department of GastroenterologyChiba University HospitalChibaJapan

Personalised recommendations